Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective

Open Access

Peer-reviewed

Research Article

Julie Chevalier ,

* E-mail: jchevalier@mapigroup.com

Affiliation Real World Strategy and Analytics, Mapi Group, Paris, France
⨯
Catherine Chamoux,

Affiliation Economie de Santé & Affaires Gouvernementales, Biogen France SAS, Nanterre, France
⨯
Florence Hammès,

Affiliation Economie de Santé & Affaires Gouvernementales, Biogen France SAS, Nanterre, France
⨯
Annie Chicoye

Current address: Institute of Health Economics and Management, ESSEC business school, Cergy-Pontoise, France

Affiliation Real World Strategy and Analytics, Mapi Group, Paris, France
⨯

Reader Comments (0)

Multiple sclerosis
Is the Subject Area "Multiple sclerosis" applicable to this article?

Thanks for your feedback.
Cost-effectiveness analysis
Is the Subject Area "Cost-effectiveness analysis" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Comparators
Is the Subject Area "Comparators" applicable to this article?

Thanks for your feedback.
Interferons
Is the Subject Area "Interferons" applicable to this article?

Thanks for your feedback.
Death rates
Is the Subject Area "Death rates" applicable to this article?

Thanks for your feedback.
France
Is the Subject Area "France" applicable to this article?

Thanks for your feedback.
Health insurance
Is the Subject Area "Health insurance" applicable to this article?

Thanks for your feedback.